AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline
Pharmaceutical Investing Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
Pharmaceutical Investing Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
RUA GOLD Completes the Second Phase of Surface Exploration and Drill Targeting at the Glamorgan Project, New Zealand
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
